MCID: BCT013
MIFTS: 55

Bacterial Pneumonia

Categories: Infectious diseases, Respiratory diseases

Aliases & Classifications for Bacterial Pneumonia

Summaries for Bacterial Pneumonia

Disease Ontology : 12 A pneumonia involving inflammation of the lungs caused by bacteria.

MalaCards based summary : Bacterial Pneumonia, also known as pneumonia due to other gram-negative bacteria, is related to mycoplasma pneumoniae pneumonia and adult respiratory distress syndrome. An important gene associated with Bacterial Pneumonia is CRP (C-Reactive Protein), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Ofloxacin and Levofloxacin have been mentioned in the context of this disorder. Affiliated tissues include lung, skin and neutrophil, and related phenotype is respiratory system.

Wikipedia : 77 Bacterial pneumonia is a type of pneumonia caused by bacterial... more...

Related Diseases for Bacterial Pneumonia

Diseases in the Pneumonia family:

Viral Pneumonia Bacterial Pneumonia

Diseases related to Bacterial Pneumonia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 205)
# Related Disease Score Top Affiliating Genes
1 mycoplasma pneumoniae pneumonia 32.4 CRP IL17A IL6
2 adult respiratory distress syndrome 30.2 CXCL8 ELANE IL6 SFTPB
3 bacterial meningitis 30.0 CRP CXCL8 IL6
4 endocarditis 30.0 CRP CXCL8 IL6 LACTB
5 acute respiratory distress syndrome 29.9 CXCL8 ELANE IL6 SFTPB SFTPD
6 pneumonia 29.9 CRP CSF3 CXCL1 CXCL8 ELANE IL6
7 avian influenza 29.8 CXCL8 IL6 SFTPD
8 deficiency anemia 29.8 CRP CSF3 IL6
9 viral pneumonia 29.7 CRP IL17A IL6
10 bronchitis 29.7 CRP CXCL8 ELANE LACTB
11 aspergillosis 29.7 ELANE SFTPD TLR4
12 interstitial lung disease 29.6 CXCL8 IL6 SFTPB SFTPD
13 peritonitis 29.6 ADA CRP CXCL8 IL6
14 chlamydia 29.5 CRP CXCL8 IL6 TLR4
15 meningitis 29.3 ADA CRP CXCL1 CXCL8 IL6 LACTB
16 respiratory failure 29.1 CRP CXCL8 ELANE SCGB1A1 SFTPB SFTPD
17 newborn respiratory distress syndrome 29.1 CXCL8 ELANE IL6 SCGB1A1 SFTPB SFTPD
18 lung disease 28.9 CXCL8 ELANE IL17A IL6 SFTPB SFTPD
19 mycobacterium tuberculosis 1 28.8 ADA IL17A TLR4
20 malaria 28.8 CRP CSF3 CXCL8 IL17A IL6 TLR4
21 periodontal disease 28.7 CRP CXCL8 DEFB4A ELANE IL17A IL6
22 asthma 28.7 CXCL1 CXCL8 ELANE IL17A IL6 SCGB1A1
23 bacterial infectious disease 28.2 CRP CSF3 CXCL8 DEFB4A ELANE IL17A
24 pulmonary disease, chronic obstructive 28.2 CRP CXCL8 ELANE IL17A IL6 SCGB1A1
25 klebsiella pneumonia 11.5
26 influenza 11.5
27 pleural empyema 11.4
28 chlamydia pneumonia 11.0
29 streptococcus pneumonia 11.0
30 aspiration pneumonia 11.0
31 myasthenic syndrome, congenital, 1a, slow-channel 10.4 CRP CXCL8
32 engraftment syndrome 10.4 CSF3 CXCL8
33 recurrent corneal erosion 10.4 CXCL8 IL6
34 cold agglutinin disease 10.4 CRP IL6
35 bagassosis 10.4 CXCL8 IL6
36 acute transverse myelitis 10.4 CXCL8 IL6
37 streptococcal toxic-shock syndrome 10.4 CXCL8 IL6
38 cryopyrin-associated periodic syndrome 10.4 CRP IL6
39 pyuria 10.4 CRP CXCL8
40 acute cholangitis 10.4 CRP IL6
41 cyclic neutropenia 10.4 CSF3 CXCL8 ELANE
42 paraquat lung 10.4 SCGB1A1 SFTPB
43 pyomyositis 10.4 CRP GPT
44 mycobacterium fortuitum 10.4 CXCL8 LACTB
45 denture stomatitis 10.4 CXCL8 IL6
46 cardiac rupture 10.4 CRP CXCL8 ELANE
47 papillary conjunctivitis 10.3 CXCL8 IL6
48 capillary leak syndrome 10.3 CXCL8 ELANE IL6
49 felty syndrome 10.3 CSF3 CXCL8
50 louse-borne relapsing fever 10.3 CRP CXCL8 IL6

Graphical network of the top 20 diseases related to Bacterial Pneumonia:



Diseases related to Bacterial Pneumonia

Symptoms & Phenotypes for Bacterial Pneumonia

MGI Mouse Phenotypes related to Bacterial Pneumonia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 respiratory system MP:0005388 9.17 ADA IL17A IL6 SCGB1A1 SFTPB SFTPD

Drugs & Therapeutics for Bacterial Pneumonia

Drugs for Bacterial Pneumonia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 198)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ofloxacin Approved Phase 4,Phase 3,Phase 2 82419-36-1 4583
2
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 100986-85-4 149096
3
Ceftaroline fosamil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 229016-73-3
4
Ceftriaxone Approved Phase 4,Phase 3,Phase 2 73384-59-5 5479530 5361919
5
Vancomycin Approved Phase 4,Phase 3,Phase 2 1404-90-6 441141 14969
6
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
7
Clavulanate Approved, Vet_approved Phase 4,Phase 2,Phase 3 58001-44-8 5280980
8
Amoxicillin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 26787-78-0 33613
9
Linezolid Approved, Investigational Phase 4,Phase 3,Phase 2 165800-03-3 441401
10
Zidovudine Approved Phase 4,Phase 3 30516-87-1 35370
11
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
12
Nevirapine Approved Phase 4 129618-40-2 4463
13
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
14
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
15
Ribavirin Approved Phase 4 36791-04-5 37542
16
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 1406-16-2
17
Vitamin D3 Approved, Nutraceutical Phase 4,Not Applicable 67-97-0 5280795 6221
18
Calcium Approved, Nutraceutical Phase 4,Not Applicable 7440-70-2 271
19
Ergocalciferol Approved, Nutraceutical Phase 4,Not Applicable 50-14-6 5280793
20
Tenofovir Experimental, Investigational Phase 4,Phase 3,Not Applicable 147127-20-6 464205
21 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Cephalosporins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Immunologic Factors Phase 4,Phase 3,Phase 2,Not Applicable
25 Immunoglobulins, Intravenous Phase 4,Phase 3,Phase 2
26 Immunoglobulins Phase 4,Phase 3,Phase 2
27 Antibodies Phase 4,Phase 3,Phase 2
28 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Cytochrome P-450 CYP1A2 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
30 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
31 Anti-Infective Agents, Urinary Phase 4,Phase 3,Phase 2,Phase 1
32 Renal Agents Phase 4,Phase 3,Phase 2,Phase 1
33 methicillin Phase 4,Phase 3
34 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Amoxicillin-Potassium Clavulanate Combination Phase 4,Phase 2,Phase 3
36 beta-Lactamase Inhibitors Phase 4,Phase 2,Phase 3
37 Clindamycin palmitate Phase 4
38 Clindamycin phosphate Phase 4
39 MF59 oil emulsion Phase 4
40 Vaccines Phase 4,Not Applicable
41 gamma-Globulins Phase 4,Phase 3,Phase 2
42 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 2
43 Anti-Retroviral Agents Phase 4,Phase 3,Not Applicable
44 Antiviral Agents Phase 4,Phase 3,Phase 2,Not Applicable
45 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4,Phase 3
46 Antimetabolites Phase 4,Phase 3
47 Micronutrients Phase 4,Not Applicable
48 Calcium, Dietary Phase 4,Not Applicable
49 Bone Density Conservation Agents Phase 4,Not Applicable
50 Calciferol Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 151)
# Name Status NCT ID Phase Drugs
1 Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia Completed NCT01524302 Phase 4 Ceftaroline;Levofloxacin
2 Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus Completed NCT01645735 Phase 4 Ceftaroline fosamil;Ceftriaxone plus vancomycin
3 Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP) Completed NCT01669980 Phase 4 Ceftaroline fosamil;IV Ceftriaxone and Vancomycin
4 Adjuvanted Influenza Vaccine in Stem Cell Transplant Completed NCT02560909 Phase 4
5 Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects Completed NCT00634569 Phase 4
6 Package of Care to Improve Retention in ART and Mortality Among Treatment Naive HIV Infected Individuals Recruiting NCT03723525 Phase 4
7 Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED) Terminated NCT00687544 Phase 4 Ribavirin (SCH 018908)
8 Correcting Anemia and Native Vitamin D Supplementation in Kidney Transplant Recipients Terminated NCT01817699 Phase 4
9 Safety and Efficacy Study of Ceftaroline in Elderly Subjects With Community-Acquired Bacterial Pneumonia Withdrawn NCT01666743 Phase 4 Ceftaroline fosamil
10 A Phase III Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia Unknown status NCT01937832 Phase 3 Faropenem;Ertapenem
11 The Effect of Ulinastatin on Bronchoalveolar Lavage Fluid of Inflammatory Factors in Patients With Ventilator-associated Pneumonia Unknown status NCT01865266 Phase 2, Phase 3 Ulinaststin for injection;placebo
12 Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID) Unknown status NCT01581593 Phase 3
13 A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia Completed NCT01371838 Phase 3 Ceftaroline;Ceftriaxone
14 Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia Completed NCT02679573 Phase 3 Delafloxacin;Moxifloxacin;Linezolid
15 Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia Completed NCT01968733 Phase 3 Solithromycin;Moxifloxacin
16 Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia Completed NCT01756339 Phase 3 Solithromycin;Moxifloxacin
17 Use of Ceftaroline in Hospitalized Patients With Community Acquired Pneumonia Completed NCT01605864 Phase 3 Efficacy of ceftaroline
18 A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia Completed NCT01561794 Phase 3 Ciprofloxacin (Cipro, BAYQ3939)
19 Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP) Completed NCT01530763 Phase 2, Phase 3 Ceftaroline fosamil;Ceftriaxone;amoxicillin clavulanate
20 Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Completed NCT00538694 Phase 3 daptomycin
21 Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13) Completed NCT02531438 Phase 3 Omadacycline;Moxifloxacin
22 Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae Completed NCT00540072 Phase 3 daptomycin
23 Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia Completed NCT02813694 Phase 3 lefamulin;Moxifloxacin
24 Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia Completed NCT02559310 Phase 3 lefamulin;Moxifloxacin;Linezolid
25 Clinical Study of S-649266 for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens Completed NCT03032380 Phase 3 S-649266;Meropenem;Linezolid
26 Study Comparing Tigecycline vs. Levofloxacin in Subjects Hospitalized With Community-Acquired Pneumonia Completed NCT00081575 Phase 3 Tigecycline;Levofloxacin
27 Study Evaluating Tigecycline vs Levofloxacin in Hospitalized With Community-Acquired Pneumonia Completed NCT00079885 Phase 3 tigecycline
28 Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia Completed NCT00621504 Phase 3 Ceftaroline fosamil for Injection;IV Ceftriaxone;Placebo;Clarithromycin
29 Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia Completed NCT00509106 Phase 3 Ceftaroline fosamil for Injection;Ceftriaxone;Placebo
30 Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus Completed NCT00124020 Phase 3 Telavancin;Vancomycin
31 Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus Completed NCT00107952 Phase 3 Telavancin;Vancomycin
32 Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia Completed NCT00080496 Phase 3 Tigecycline;Imipenem;Cilastatin
33 Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008) Completed NCT02070757 Phase 3 ceftolozane/tazobactam;Meropenem
34 Trial of Colistin Versus Meropenem in Ventilator-associated Pneumonia (VAP) (CR-GNB) Completed NCT01292031 Phase 3 Colistin;Meropenem
35 A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE) Completed NCT01970371 Phase 3 plazomicin;colistin;meropenem;tigecycline;antibiotic of Investigator's choice
36 Study of Fluid Collection of the Chest in Children With Pneumonia Completed NCT00202826 Phase 3
37 Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults Completed NCT02168946 Phase 3 Vabomere;Best Available Therapy
38 Inhaled Corticosteroids in U-5 Children With Acute Respiratory Infection in Uganda: A Randomised Trial Completed NCT01868113 Phase 3 Inhaled corticosteroid
39 Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013) Completed NCT02452047 Phase 3 Imipenem+Cilastatin/Relebactam;Colistimethate sodium (CMS);Imipenem+Cilastatin;Placebo to CMS
40 Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema (DTPA Trial) Completed NCT01717742 Phase 3 tPA;DNase
41 Tedizolid Phosphate (TR-701 FA) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002) Completed NCT02019420 Phase 3 Tedizolid phosphate IV;Linezolid
42 A Study of Three Drugs Plus Zidovudine in the Prevention of Infections in HIV-Infected Patients Completed NCT00000991 Phase 3 Pentamidine isethionate;Sulfamethoxazole-Trimethoprim;Dapsone;Zidovudine
43 Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD) Completed NCT00538915 Phase 3
44 Indiaclen Short Course Amoxycillin Therapy for Pneumonia With Wheeze Completed NCT00407394 Phase 3 Amoxycillin
45 A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases Completed NCT01012323 Phase 3
46 Immune Globulin Subcutaenous (Human), 20% Completed NCT01412385 Phase 2, Phase 3
47 Gammagard Liquid and rHuPH20 in PID Completed NCT00814320 Phase 3
48 Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study) Completed NCT01461018 Phase 3
49 The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP) Completed NCT01189487 Phase 3 ampicillin sodium/sulbactam sodium
50 PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV) Completed NCT01099579 Phase 3 Atazanavir powder;Ritonavir oral solution;Atazanavir capsules;Ritonavir capsules

Search NIH Clinical Center for Bacterial Pneumonia

Cochrane evidence based reviews: pneumonia, bacterial

Genetic Tests for Bacterial Pneumonia

Anatomical Context for Bacterial Pneumonia

MalaCards organs/tissues related to Bacterial Pneumonia:

42
Lung, Skin, Neutrophil, Testes, Colon, Liver, Bone

Publications for Bacterial Pneumonia

Articles related to Bacterial Pneumonia:

(show top 50) (show all 634)
# Title Authors Year
1
The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance. ( 30596308 )
2019
2
Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia. ( 30649434 )
2019
3
ABL kinase inhibition promotes lung regeneration through expansion of an SCGB1A1+ SPC+ cell population following bacterial pneumonia. ( 30655340 )
2019
4
Recurrent bacterial pneumonia in Irish Wolfhounds: Clinical findings and etiological studies. ( 30666726 )
2019
5
Antibacterial Activity of Lefamulin Against Pathogens Most Commonly Causing Community-Acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015-2016). ( 30670415 )
2019
6
Efficacy and Safety of IV-to-Oral Lefamulin, a Pleuromutilin Antibiotic, for Treatment of Community-Acquired Bacterial Pneumonia: The Phase 3 LEAP 1 Trial. ( 30722059 )
2019
7
Omadacycline for Community-Acquired Bacterial Pneumonia. ( 30726692 )
2019
8
A spatial analysis of geographic variation and factors associated with hospitalization for bacterial pneumonia in Korea. ( 30786908 )
2019
9
Solithromycin monotherapy for treatment of community-acquired bacterial pneumonia: a meta-analysis of randomized controlled trials. ( 30810253 )
2019
10
Geographical and temporal variation in the frequency and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bacterial pneumonia: results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997-2016). ( 30843070 )
2019
11
Computational screening of potential drug targets for pathogens causing bacterial pneumonia. ( 30914386 )
2019
12
Community-acquired bacterial pneumonia in adult HIV-infected patients. ( 29976111 )
2018
13
Aberrant Th2 inflammation drives dysfunction of alveolar macrophages and susceptibility to bacterial pneumonia. ( 28260794 )
2018
14
Bacterial pneumonia in patients with liver cirrhosis, with or without HIV co-infection: a possible definition of antibiotic prophylaxis associated pneumonia (APAP). ( 28851249 )
2018
15
Cost Drivers of a Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial. ( 29020279 )
2018
16
Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia. ( 29038277 )
2018
17
The TLR4-PAR1 Axis Regulates Bone Marrow Mesenchymal Stromal Cell Survival and Therapeutic Capacity in Experimental Bacterial Pneumonia. ( 29396891 )
2018
18
Bacterial Pneumonia in Elderly Japanese Populations. ( 29434484 )
2018
19
Effective Antimicrobial Stewardship Strategies for Cost-effective Utilization of Telavancin for the Treatment of Patients With Hospital-acquired Bacterial Pneumonia Caused by Staphylococcus aureus. ( 29454592 )
2018
20
Recurrent bacterial pneumonia due to immunoglobulin G2 subclass deficiency after allogeneic hematopoietic stem cell transplantation: Efficacy of immunoglobulin replacement. ( 29512243 )
2018
21
SCH79797 improves outcomes in experimental bacterial pneumonia by boosting neutrophil killing and direct antibiotic activity. ( 29514266 )
2018
22
15-epi-Lipoxin A4, Resolvin D2, and Resolvin D3 Induce NF-κB Regulators in Bacterial Pneumonia. ( 29523657 )
2018
23
Cigarette smoke exposure worsens acute lung injury in antibiotic-treated bacterial pneumonia in mice. ( 29543040 )
2018
24
Early Bacterial Pneumonia After Hepatic Transplantation: Epidemiologic Profile. ( 29579836 )
2018
25
Erratum for Drusano et al., "Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia". ( 29588353 )
2018
26
Bacterial pneumonia in kidney transplant recipients. ( 29605219 )
2018
27
Inhibition of IP6K1 suppresses neutrophil-mediated pulmonary damage in bacterial pneumonia. ( 29618559 )
2018
28
Clarithromycin expands CD11b+Gr-1+ cells via the STAT3/Bv8 axis to ameliorate lethal endotoxic shock and post-influenza bacterial pneumonia. ( 29621339 )
2018
29
Secondary Bacterial Pneumonia by Staphylococcus aureus Following Influenza A Infection Is SaeR/S Dependent. ( 29668950 )
2018
30
Lectin Microarray Combined with Mass Spectrometry Identifies Haptoglobin-Related Protein (HPR) as a Potential Serologic Biomarker for Separating Nonbacterial Pneumonia from Bacterial Pneumonia in Childhood. ( 29785832 )
2018
31
Macrolide Resistance in Cases of Community-Acquired Bacterial Pneumonia in the Emergency Department. ( 29789175 )
2018
32
Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia. ( 30010650 )
2018
33
Interleukin-5, interleukin-6, interferon induced protein-10, procalcitonin and C-reactive protein among mechanically ventilated severe community-acquired viral and bacterial pneumonia patients. ( 30055898 )
2018
34
C-reactive protein and procalcitonin to discriminate between tuberculosis, Pneumocystis jirovecii pneumonia, and bacterial pneumonia in HIV-infected inpatients meeting WHO criteria for seriously ill: a prospective cohort study. ( 30107791 )
2018
35
Laboratory Investigation of Trends in Bacterial Pneumonia in Cheonan, Korea, from January 2008 to September 2017. ( 30178647 )
2018
36
Corrigendum: Elucidation of Bacterial Pneumonia-Causing Pathogens in Patients with Respiratory Viral Infection. ( 30238717 )
2018
37
Antimicrobial activity of ceftaroline and comparator agents tested against organisms isolated from patients with community-acquired bacterial pneumonia in Europe, Asia, and Latin America. ( 30315990 )
2018
38
A Comparison of the Mortality Risk Associated With Ventilator-Acquired Bacterial Pneumonia and Nonventilator ICU-Acquired Bacterial Pneumonia. ( 30407949 )
2018
39
CCR2 mediates increased susceptibility to post-H1N1 bacterial pneumonia by limiting dendritic cell induction of IL-17. ( 30498200 )
2018
40
Respiratory Viral Infection-Induced Microbiome Alterations and Secondary Bacterial Pneumonia. ( 30505304 )
2018
41
YKL-40 levels are associated with disease severity and prognosis of viral pneumonia, but not available in bacterial pneumonia in children. ( 30514252 )
2018
42
Innate Immune Cell Suppression and the Link With Secondary Lung Bacterial Pneumonia. ( 30619303 )
2018
43
Immunomodulators targeting MARCO expression improve resistance to postinfluenza bacterial pneumonia. ( 28408365 )
2017
44
The mito-DAMP cardiolipin blocks IL-10 production causing persistent inflammation during bacterial pneumonia. ( 28074841 )
2017
45
Participation of Necroptosis in the Host Response to Acute Bacterial Pneumonia. ( 28125817 )
2017
46
Postviral Complications: Bacterial Pneumonia. ( 28159155 )
2017
47
IL-36γ is a crucial proximal component of protective type-1-mediated lung mucosal immunity in Gram-positive and -negative bacterial pneumonia. ( 28176791 )
2017
48
Fluorocycline TP-271 Is Potent against Complicated Community-Acquired Bacterial Pneumonia Pathogens. ( 28251179 )
2017
49
Hot Topics in Primary Care: Community-Acquired Bacterial Pneumonia: Is There Anything New? ( 28375402 )
2017
50
Pore-forming toxin-mediated ion dysregulation leads to death receptor-independent necroptosis of lung epithelial cells during bacterial pneumonia. ( 28387756 )
2017

Variations for Bacterial Pneumonia

Expression for Bacterial Pneumonia

Search GEO for disease gene expression data for Bacterial Pneumonia.

Pathways for Bacterial Pneumonia

Pathways related to Bacterial Pneumonia according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.89 CRP CSF3 CXCL1 CXCL8 DEFB4A ELANE
2
Show member pathways
13.28 CSF3 CXCL1 CXCL8 IL17A IL22 IL6
3
Show member pathways
13.17 CSF3 CXCL1 CXCL8 IL17A IL22 IL6
4
Show member pathways
13.05 CXCL1 CXCL8 IL6 SFTPD TLR4
5
Show member pathways
12.46 IL17A IL22 IL6 TLR4
6
Show member pathways
12.07 CSF3 CXCL1 CXCL8 DEFB4A IL17A IL6
7
Show member pathways
12.05 CXCL8 DEFB4A IL6 SFTPD TLR4
8
Show member pathways
11.97 IL17A IL22 IL6 TLR4
9
Show member pathways
11.95 CXCL8 IL17A IL22 IL6
10 11.92 CXCL1 CXCL8 IL6 TLR4
11 11.84 CXCL8 IL17A IL6
12 11.81 CXCL1 CXCL8 IL6
13 11.78 CXCL1 CXCL8 IL6 TLR4
14 11.71 CXCL1 CXCL8 IL6 TLR4
15 11.65 CXCL8 IL6 TLR4
16 11.6 CXCL1 IL17A IL6
17 11.54 CSF3 CXCL8 IL6
18 11.51 CXCL1 CXCL8 IL17A IL6 TLR4
19 11.45 CXCL1 CXCL8 IL6 TLR4
20 11.36 CSF3 CXCL1 CXCL8 IL6
21 11.31 CSF3 CXCL8 IL6 TLR4
22 11.23 IL17A IL22 IL6
23 11.15 CSF3 CXCL1 IL6
24
Show member pathways
11.07 CSF3 CXCL1 CXCL8 IL17A IL6 TLR4
25 10.91 CRP CXCL8 IL6
26 10.9 CSF3 CXCL1 CXCL8 IL17A IL22 IL6
27 10.66 CSF3 CXCL1 CXCL8 IL17A IL22 IL6

GO Terms for Bacterial Pneumonia

Cellular components related to Bacterial Pneumonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 CRP CSF3 CXCL1 CXCL8 DEFB4A ELANE
2 extracellular space GO:0005615 9.47 ADA CRP CSF3 CXCL1 CXCL8 DEFB4A

Biological processes related to Bacterial Pneumonia according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 defense response to bacterium GO:0042742 9.8 DEFB4A ELANE SFTPD TLR4
2 regulation of signaling receptor activity GO:0010469 9.8 CSF3 CXCL1 CXCL8 IL17A IL22 IL6
3 defense response to Gram-positive bacterium GO:0050830 9.71 CRP DEFB4A IL6
4 defense response to Gram-negative bacterium GO:0050829 9.7 DEFB4A IL6 TLR4
5 cellular response to lipopolysaccharide GO:0071222 9.65 CSF3 CXCL1 CXCL8 IL6 TLR4
6 response to glucocorticoid GO:0051384 9.63 IL22 IL6 SCGB1A1
7 cytokine-mediated signaling pathway GO:0019221 9.63 CSF3 CXCL1 CXCL8 IL17A IL22 IL6
8 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.61 CXCL1 CXCL8 DEFB4A
9 acute-phase response GO:0006953 9.58 CRP IL22 IL6
10 positive regulation of chemokine production GO:0032722 9.57 IL6 TLR4
11 embryonic digestive tract development GO:0048566 9.56 ADA CXCL8
12 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.55 IL17A TLR4
13 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.51 ELANE TLR4
14 immune response GO:0006955 9.5 CSF3 CXCL1 CXCL8 DEFB4A IL17A IL6
15 negative regulation of lipid storage GO:0010888 9.48 CRP IL6
16 negative regulation of chemokine biosynthetic process GO:0045079 9.37 ELANE IL6
17 inflammatory response GO:0006954 9.17 CRP CXCL1 CXCL8 IL17A IL22 IL6

Molecular functions related to Bacterial Pneumonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.1 CSF3 CXCL1 CXCL8 IL17A IL22 IL6

Sources for Bacterial Pneumonia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....